Stockscreener 앱 받기
0.00
100.00%
-0.048
시간 외 거래:
.05
0.05
+
Io Biotech Inc 주식(IOBT)의 최신 뉴스
Metastatic Melanoma Therapeutics Market Study Highlights How Industry Demand Is Evolving - openPR.com
Silicone Tubing for Biotech Market Growth to 2035 Driven by Single-Use SystemsNews and Statistics - IndexBox
Layoff Tracker: Kolon TissueGene cuts 37 US staffers after Phase 3 fail - BioSpace
Fierce Biotech Layoff Tracker 2026: Kolon cuts workforce after ph. 3 fail; Sanofi sheds 229 staffers - Fierce Biotech
Cogent Biosciences (COGT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance
All You Need to Know About Korro Bio, Inc. (KRRO) Rating Upgrade to Buy - finance.yahoo.com
Ascentage Pharma Appoints Dr. Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer - GlobeNewswire
Ascentage Pharma appoints Miyara, Ziegler to lead global expansion - scanx.trade
All You Need to Know About Data IO (DAIO) Rating Upgrade to Buy - Yahoo Finance
FDA scientists question Capricor data; Legend CEO steps down - BioPharma Dive
IO Biotech, Inc. Revenue Breakdown – OTC:IOBTQ - TradingView
Adaptive Biotechnologies (ADPT) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Zealand Pharma gets its US marketing leader from Lilly; Bexorg turns to Biohaven for CSO hire - Endpoints News
Elevara Medicines appoints biotech veteran as CEO - The Pharma Letter
Elevara Medicines Appoints Biotech Veteran as CEO - markets.businessinsider.com
Price to sales forward of IO Biotech, Inc. – OTC:IOBTQ - TradingView
Price to earnings forward of IO Biotech, Inc. – OTC:IOBTQ - TradingView
Enterprise value to revenue forward of IO Biotech, Inc. – OTC:IOBTQ - TradingView
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.18% - Investing.com
Years of life lost in patients with a false-negative diagnosis of primary melanoma. A prospective study of the German Central Malignant Melanoma Registry involving 9063 patients over 28 years - nature.com
Cancer Vaccines Market Unlocking New Revenue Opportunities and Strategic Expansion by 2034 – DelveInsight | Dendreon Pharma, Candel Therapeutics, GlaxoSmithKline, Merck, Aduro Biotech, Astrazeneca - Barchart.com
Cancer Vaccines Market Unlocking New Revenue Opportunities - openPR.com
IO Biotech Inc (IOBT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
IO Biotech, Inc. Actuals & Estimates (OTC:IOBTQ) - TradingView
All You Need to Know About Immix Biopharma (IMMX) Rating Upgrade to Buy - Yahoo Finance
IO Biotech Inc (IOBT) Institutional Confidence - TradingKey
IO Biotech Inc (IOBT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
IO Biotech Inc (IOBT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
IO Biotech Inc (IOBT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
IO Biotech Inc (IOBT) Valuation: PE, PB & Fair Value Analysis - TradingKey
IO Biotech Inc (IOBT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
IO Biotech Inc (IOBT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
IO Biotech Inc (IOBT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Here's Why PDS Biotechnology (PDSB) Could be Great Choice for a Bottom Fisher - Yahoo Finance
IO Biotech (IOBT) common stock removed from Nasdaq in voluntary withdrawal - Stock Titan
Bionano Genomics (BNGO) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Bears are Losing Control Over Si-Bone (SIBN), Here's Why It's a 'Buy' Now - Yahoo Finance
Major IO Biotech (IOBT) shareholder updates 27.4% stake as company enters Chapter 7 - Stock Titan
IOBTQ Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
IO Biotech Holds Steady at $0.05: Navigating Extremely Low Valuation TerritoryDay Trade Opportunities - dars.gov.et
IO Biotech (IOBT) Holds Steady at $0.05 as Key Support and Resistance ConvergeTrend Continuation Trade - The Legal Advocate
IO Biotech Q3 2025 Earnings: EPS Beat of 60.67% Surprise, but No Revenue from Pre-Commercial PipelineEstimate Revision Count - The Legal Advocate
0.00%
3.22%
자본화:
|
볼륨(24시간):